-
Mashup Score: 28Safety of Continuing Trastuzumab for Mild Cardiotoxicity: A Cardiovascular Magnetic Resonance Imaging Study - 10 month(s) ago
The safety of continuing human epidermal growth factor receptor 2 (HER2)–targeted therapy in women with mild cardiotoxicity remains unclear. We performed a retrospective matched cohort study of 14 patients with human epidermal growth factor receptor 2–positive breast cancer receiving sequential anthracycline and trastuzumab therapy, nested within the Evaluation of Myocardial Changes During Breast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI (EMBRACE-MRI) trial. Among patients who developed cardiotoxicity and were treated with heart failure therapy, we compared those who had trastuzumab therapy interrupted to a matched cohort who continued trastuzumab therapy.
Source: www.cjcopen.caCategories: General Medicine News, Cardiologists1Tweet
-
Mashup Score: 9Energy and Greenhouse Gas Emission Savings Associated with Implementation of an Abbreviated Cardiac MRI Protocol - 11 month(s) ago
Supplemental material is available for this article. See also the article by Lenkinski and Rofsky in this issue. See also the article by McKee et al in this issue.
Source: pubs.rsna.orgCategories: General Medicine News, Cardiologists1Tweet
Very small (14 pts) retrospective pilot matched cohort study nested with EMBRACE-MRI - continuing vs holding trastuzumab in CTRCD (led by our resident Sivisan) - at 2.5 yr f/u no diff in MRI LVEF<40%, LVEF, T1, T2, ECV, and post therapy QOL, VO2peak. https://t.co/cAOBGB4XwB